All In Biotech

Drug Trial Radar · NCT07331194

Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans

A Single-Center, Open-Label, Randomized, Crossover Phase I Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of Two Different Formulations of HMPL-523 Acetate Tablets in Chinese Healthy Participants

Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

54

Actual

Start

Oct 28, 2025

Primary completion

Nov 28, 2025

Study completion Feb 2, 2026

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Jan 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Two formulations containing the same active pharmaceutical ingredient are considered bioequivalent if their relative bioavailability (rate and extent of drug absorption) falls within acceptable predetermined limits after administration at the same molar dose. Formulations with bioequivalence are considered to act comparably in vivo, i.e., similar in terms of safety and efficacy. This study aims to evaluate the pharmacokinetic (PK) profile and bioequivalence of the original and modified formulations of HMPL-523 acetate tablets in healthy participants to bridge the safety and efficacy of the modified formulation of HMPL 523 acetate tablets in humans.

Conditions

  • Healthy

Interventions

  • HMPL-523 Acetate Tablets (Test Formulation)Drug

    The trial participants were administered the drug on the first day of each cycle. dose 300mg

  • HMPL-523 Acetate Tablets (Reference Formulation)Drug

    The trial participants were administered the drug on the first day of each cycle. dose 300mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK parametersTime frame: up to two months
  2. PK parametersTime frame: up to two months
  3. PK parametersTime frame: up to two months
  4. PK parametersTime frame: up to two months
  5. PK parametersTime frame: up to two months
  6. The bioequivalence of two different drug product formulations of HMPL 523 acetate tabletsTime frame: up to two months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Shandong First Medical University

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.